Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 8-K (Current Report)
Date: June 19, 2019
Event: Announcement of a definitive agreement to acquire DOSE Medical Corporation, a developer of micro-invasive, sustained-release, bioerodible drug delivery platforms for retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME).
Key Financial Metrics and Transaction Terms
This filing details a merger agreement rather than periodic financial results. Key financial terms include:
- Upfront Purchase Price: $2.5 million, funded by Glaukos' cash on hand.
- Regulatory Milestone Payments (FDA): Between $5.0 million and $22.5 million if products receive FDA approval within 10 years.
- Regulatory Milestone Payments (EMA): $1.25 million or $2.5 million if products receive European Medicines Agency approval within 10 years.
- Royalties: 5% of net sales of approved DOSE products, payable quarterly for 10 years following FDA approval.
- Sales Milestone Payments: Additional earn-outs of $7.5 million and $20.0 million upon achieving specific net sales targets.
- Buyout Option: Glaukos may elect to buy out future earn-outs and royalties for amounts between $10.0 million and $55.0 million following FDA approval.
Financial Statements: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for Glaukos Corporation.
Material Changes and Background
The acquisition represents a strategic re-entry into a former subsidiary. DOSE was previously a wholly-owned subsidiary of Glaukos before being spun out in 2010. Glaukos has previously acquired specific assets from DOSE, including the iDose product line in 2015 and an intraocular pressure sensor system in 2017. The transaction involves related parties, as two Glaukos board members serve on DOSE's board, and certain Glaukos management and directors hold equity in DOSE. The terms were approved by a special committee of independent directors.
Outlook, Risks, and Contingencies
- Closing Timeline: Expected to close during the current quarter (Q2 2019), subject to customary conditions.
- Contingencies: Significant portions of the purchase price are contingent on future regulatory approvals (FDA/EMA) and sales performance over a 10-year period.
- Risk Disclosure: The filing explicitly states that representations and warranties in the Merger Agreement are for contractual risk allocation and should not be relied upon as factual characterizations of the current state of affairs. Information may change after the agreement date.
Investor Verification Checklist
- Verify the exact closing date and any conditions precedent that may delay the transaction.
- Review the full text of the Merger Agreement (Exhibit 99.2) for specific definitions of "net sales" and the precise sales milestones triggering the $7.5 million and $20.0 million payments.
- Assess the current development stage of DOSE's drug delivery platforms to evaluate the probability of achieving the regulatory milestones.
- Confirm the extent of related-party transactions and equity holdings by Glaukos directors in DOSE to understand potential conflicts of interest.
- Check subsequent filings for updates on the buyout option election if FDA approval is granted.